Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis

December 12th 2022

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

Selinexor/Ruxolitinib Combo Reduces Spleen Volume in Myelofibrosis

December 11th 2022

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML

December 10th 2022

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

EMA Accepts Marketing Authorization Application for Momelotinib in Myelofibrosis

December 2nd 2022

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

Dr. Schiller on JAK Inhibitors in Myelofibrosis

December 2nd 2022

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis

November 28th 2022

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

Dr. Rampal on the Future Research of CDK4/6 Inhibitors in MPNs

November 22nd 2022

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

November 17th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Dr. Schiller on Addressing Unmet Needs in Myelofibrosis Treatment

November 16th 2022

Gary J. Schiller, MD, discusses several areas of unmet need in myelofibrosis, and how to potentially address these challenges.

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction

November 9th 2022

Ahead of the 40th Annual Chemotherapy Foundation Symposium, Pinkal Desai, MD, addresses the evolving role of targeted therapies in MDS and how clinicians can characterize MDS risk.

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS

November 2nd 2022

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis

November 1st 2022

The European Commission has granted an orphan drug designation to selinexor for the treatment of patients with myelofibrosis.

Luspatercept Improves Transfusion Independence in Very Low– to Intermediate-Risk MDS

October 31st 2022

Luspatercept generated a statistically significant improvement in red blood cell transfusion independence with concurrent hemoglobin increase vs epoetin alfa in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who require RBC transfusions, meeting the primary end point of the phase 3 COMMANDS trial.

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Luspatercept Demonstrates Long-Term Anemia Benefit in Lower-Risk MDS

October 7th 2022

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera

October 7th 2022

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Momelotinib Improves OS in Patients With Myelofibrosis and Low Platelet Counts

October 3rd 2022

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.